Suboptimal irritable bowel syndrome (IBS) management frequently results from delayed diagnosis, underappreciation of disease impact on the part of providers, and inadequate symptom control despite therapy. There is a strong need for clinician education on strategies to promote more accurate disease assessment and improved treatment selection. In addition, clinicians also face challenges related to the need to keep pace with developments in understanding of the disease. For example, although recognition of the role of dysbiosis in IBS pathogenesis has grown significantly in recent years, the place of therapies targeting the gut microbiota has yet to be firmly established. Presently, several studies to address this issue are ongoing. As the results of these investigations become available, clinicians will require detailed education, along with expert guidance, to determine how to incorporate these findings into their therapeutic decision-making.